MaxCyteMXCT +3.54%62 Gross Margin % is 83.74% as of Mar. 2026, which is 6% below its 10-year median of 88.74. GuruFocus rates MXCT with a GF Score™ of 62/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 805 Medical Devices & Instruments companies, MaxCyte ranks better than 91.8% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. MaxCyte's Gross Profit for the
three
months ended in Mar. 2026 was $8.08 Mil. MaxCyte's Revenue for the
three
months ended in Mar. 2026 was $9.65 Mil. Therefore, MaxCyte's Gross Margin % for the quarter that ended in Mar. 2026 was 83.74%.
Warning Sign:
MaxCyte Inc gross margin has been in long-term decline. The average rate of decline per year is -2.1%.
The historical rank and industry rank for MaxCyte's Gross Margin % or its related term are showing as below:
MXCT'
s Gross Margin % Range Over the Past 10 Years
Min: 80.51 Med: 88.74 Max: 89.61
Current: 80.51
During the past 13 years, the highestGross Margin % of MaxCyte was 89.61%. The lowest was 80.51%. And the median was 88.74%.
MXCT's Gross Margin % is ranked better than 91.8% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 52.07
vs MXCT: 80.51
MaxCyte had a gross margin of 83.74% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for MaxCyte was -2.10% per year.
MaxCyte (NAS:MXCT) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
MaxCyte had a gross margin of 83.74% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
MaxCyte Gross Margin % Related Terms
MaxCyte Gross Margin % Historical Data
* Premium members only.
The historical data trend for MaxCyte's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MXCT vs RCEL, NNOX, SNWV: Gross Margin % Comparison
For the Medical Devices subindustry, MaxCyte's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Gross Margin % distribution charts can be found below:
* The bar in red indicates where MaxCyte's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
MaxCyte (MXCT) has a Gross Margin % of 83.74% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on MaxCyte and its competitors. This is near median its historical median of 88.74. Over the past decade, MaxCyte's Gross Margin % has ranged from 80.51 to 89.61. According to the industry distribution chart, MaxCyte ranks #66 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 8.2%.
Is MaxCyte's Gross Margin % too high?
MaxCyte's current Gross Margin % of 83.74% is near median its 10-year median of 88.74. Over the past 10 years, this metric has ranged from a low of 80.51 to a high of 89.61. The Medical Devices & Instruments industry median Gross Margin % is 52.07. MaxCyte's value of 83.74% is 60.8% above this industry median. Based on the distribution chart, MaxCyte ranks #66 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MaxCyte has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Gross Margin % compare to RCEL and NNOX?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #66 out of 805 companies for Gross Margin %. This places MaxCyte in the top 8% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 52.07. MaxCyte's value of 83.74% is 60.8% above this benchmark. Historically, MaxCyte's own Gross Margin % has ranged from 80.51 to 89.61 over the past decade. While the company's 10-year median is 88.74 vs. the industry median of 52.07, MaxCyte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MaxCyte's current Gross Margin % of 83.74% is 60.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on MaxCyte and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current Gross Margin % is 83.74%, which is near median its own 10-year median of 88.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.32 — trading 48.8% below its estimated fair value. The current Gross Margin % is 83.74%, which is near median its 10-year median of 88.74 and 60.8% above the Medical Devices & Instruments industry median of 52.07. MaxCyte's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For MaxCyte (MXCT), the current Gross Margin % is 83.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.32 is trading 48.8% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Gross Margin %: 83.74% (near median its 10-year median of 88.74)
GF Value™: $2.57 vs. price of $1.32 (48.8% below fair value)
Industry Position: 60.8% above the Medical Devices & Instruments median (#66 of 805)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
62GF Score
Get the complete analysis for MXCT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
